Advanced Filters
noise
Found 568 clinical trials
M Marc Clausen, MA

Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing

Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - …

18 years of age All Phase N/A
D Donglai Lv, MD

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced …

18 years of age All Phase 1
H Hussain Hassan

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design This is …

18 years of age All Phase N/A

A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.

45 years of age Female Phase N/A

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

18 years of age Female Phase N/A
N NOUGARET Stephanie, MD

Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

18 years of age Female Phase N/A
P Prof Udai Banerji, MBBS MD DNB PhD FRCP

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells …

18 years of age Female Phase 1
S Shefqet Halili, MD

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Background Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women …

18 years of age Female Phase 2
R Ronnie Shappira, MD

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.

18 years of age Female Phase 2
S Site Public Contact

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study …

18 years of age All Phase 1

Simplify language using AI